Induction of chondrogenesis of human placenta-derived mesenchymal stem cells via heparin-grafted human fibroblast derived matrix
Source abstract
Abstract
Abstract Background Formation of mature and functional articular cartilage is still challenging in cartilage tissue engineering. This study investigates the potential of using heparin-grafted decellularized extracellular matrix (ECM) as a novel growth factor delivery platform towards human placenta-derived mesenchymal stem cells (hPMSCs) chondrogenic differentiation. Human fibroblast-derived extracellular matrix (hFDM) is naturally obtained from in vitro-cultured human lung fibroblasts via a mild decellularization process. hFDM was then conjugated with heparin via N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) chemistry and subject to transforming growth factor (TGF)-β1 immobilization. Once heparin grafted-hFDM (hFDM-hep) and hPMSCs were co-embedded into collagen gel, they were examined for in vitro and in vivo chondrogenesis of hPMSCs for 4 weeks. Results We identified heparin moieties on hFDM via toluidine blue O assay and Fourier transform infrared spectroscopy, respectively. We found out that collagen spheroids containing hFDM-hep and TGF-β1 exhibited a sustained release of growth factor for 28 days in vitro. Chondrogenesis of hPMSCs in vitro was supported by accumulated glycosaminoglycan (GAG) content and upregulated chondrogenic specific markers (collagen II, aggrecan, Sox9). Meanwhile, PKH26 - labeled hPMSCs incorporated collagen with either hFDM or hFDM-hep was pre-conditioned in a chondrogenic media for 3 days and subcutaneously implanted in the back of nude mice for 4 weeks. The implanted collagen spheroids containing both hPMSCs and hFDM-hep retained more viable hPMSCs and showed higher level of chondrogenic differentiation, based on immunostaining of collagen type II over collagen alone or Col/hFDM group. In addition, histological examination showed more positive signals of GAG via Safranin-O staining. Conclusion TGF-β1-immobilized hFDM-hep can provide an appropriate microenvironment for chondrogenic differentiation of hPMSCs in 3D collagen spheroid.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Tissue Engineering and Regenerative Medicine · Mesenchymal stem cell research · Osteoarthritis Treatment and Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for Biomaterials, Korea Institute of Science and Technology, Seoul 02792, South Korea.
Department of Biotechnology, Korea University, Seoul 02841, South Korea.
Division of Bio-Medical Science and Technology, KIST School, Korea University of Science and Technology (UST), Seoul 02792, South Korea.
Funding
Korea Health Industry Development Institute
References (29)
Show source-provided references
1. 10.1038/nrdp.2016.7210.1038/nrdp.2016.72 ↗
2. 10.1007/s00167-008-0663-210.1007/s00167-008-0663-2 ↗
3. 10.1302/0301-620X.91B5.2183210.1302/0301-620X.91B5.21832 ↗
4. 10.22203/eCM.v027sa0310.22203/eCM.v027sa03 ↗
5. 10.1038/nmat244110.1038/nmat2441 ↗
6. 10.1038/nnano.2010.24610.1038/nnano.2010.246 ↗
7. 10.1126/science.122245410.1126/science.1222454 ↗
8. 10.1098/rsif.2007.022010.1098/rsif.2007.0220 ↗
9. 10.1038/nrm362010.1038/nrm3620 ↗
10. 10.1242/jcs.02382010.1242/jcs.023820 ↗
11. 10.1517/14712598.2010.53407910.1517/14712598.2010.534079 ↗
12. 10.1039/C4BM00246F10.1039/C4BM00246F ↗
13. Jeon J Lee MS and Yang HS. Differentiated osteoblasts derived decellularized extracellular matrix to promote osteogenic differentiation. Biomater Res. 2018;22:4.10.1186/s40824-018-0115-0 ↗
14. 10.1203/PDR.0b013e31816c5bc310.1203/PDR.0b013e31816c5bc3 ↗
15. Dhandayuthapani B, Yoshida Y, Maekawa T, Kumar DS. Polymeric scaffolds in tissue engineering application: a review. Inter J Polymer Sci. 2011;290602:19.
16. 10.1126/science.284.5411.14310.1126/science.284.5411.143 ↗
17. Cho H Lee A and Kim K. The effect of serum types on Chondrogenic differentiation of adipose-derived stem cells. Biomater Res. 2018;22:6.10.1186/s40824-018-0116-z ↗
18. 10.1016/j.arr.2010.08.00510.1016/j.arr.2010.08.005 ↗
19. Bobis S, Jarocha D, Majka M. Mesenchymal stem cells: characteristics and clinical applications. Folia Histochem Cytobiol. 2006;44:215–230.
20. 10.4252/wjsc.v4.i6.5310.4252/wjsc.v4.i6.53 ↗
21. 10.1016/j.placenta.2010.12.01610.1016/j.placenta.2010.12.016 ↗
22. 10.1016/j.biomaterials.2015.01.05410.1016/j.biomaterials.2015.01.054 ↗
23. 10.1016/j.biomaterials.2016.01.04810.1016/j.biomaterials.2016.01.048 ↗
24. 10.1007/s11095-006-9039-910.1007/s11095-006-9039-9 ↗
25. 10.1016/j.jconrel.2014.08.02610.1016/j.jconrel.2014.08.026 ↗
26. 10.1016/j.tips.2014.03.00510.1016/j.tips.2014.03.005 ↗
27. 10.1016/S1359-6101(02)00004-710.1016/S1359-6101(02)00004-7 ↗
28. 10.1016/j.biomaterials.2011.07.01510.1016/j.biomaterials.2011.07.015 ↗
29. 10.1002/mabi.20170015810.1002/mabi.201700158 ↗